Insurance giant Aetna Inc. (AET) will be reporting its fourth quarter earnings Friday before the market opens, with analysts expecting to see a strong quarter for the company.

Going into tomorrow's earnings report, analysts are expecting to see Aetna report earnings of $0.62 per share, up from $0.40 during the same period last year.

U.S. stock futures are mixed this morning, as investors await jobless-claims data and earnings report from Merck (MRK). Futures on the Dow Jones Industrial Average rose 7 points to 11,992 and S&P 500 futures fell 0.40 point to 1,299.60. Nasdaq 100 futures fell 3.50 to 2,316.25.

The Dow index gained 1.81 points or 0.02% to close at 12,042 yesterday.

Data on weekly jobless claims and fourth quarter productivity will be released at 8:30 a.m. ET. The ISM report on service sector activity in January and factory orders for December will both be released at 10 a.m. ET.

US retailers such as Wal-Mart Stores (WMT) are scheduled to report same-store sales for January.

Analyst Upgrades

• Exxon Mobil (XOM) and BB&T (BBT) to outperform from perform at Oppenheimer.
• D.R. Horton (DHI) upgraded to outperform from market perform at Wells Fargo.
• Meritage Homes (MTH), Old Dominion Freight (ODFL) and Heartland Payment (HPY) to outperform from market perform at Wells Fargo.
• Toll Brothers (TOL) to overweight from equal weight at Barclays.
• Hershey (HSY) to buy from neutral at Janney Capital.
• UnitedHealth (UNH), Cigna (CI) and Allscripts (MDRX) to buy from hold at Deutsche Bank.
• Nationwide Health (NHP) to outperform from market perform at JMP Securities.
• Reynolds American (RAI) to buy from neutral at UBS.
• Adtran (ADTN), PG&E (PCG) and Wisconsin Energy (WEC) to overweight from equal weight at Morgan Stanley.

Analyst Upgrades

• Goldman upgraded Eaton (ETN) to conviction buy from neutral.
• AECOM Technology (ACM) was upgraded to outperform from neutral at Macquarie.
• Piper Jaffray upgraded Hologic (HOLX), Gen-Probe (GPRO) and Qiagen (QGEN) to overweight from neutral.
• GeoMet (GMET) was upgraded to accumulate from neutral at Global Hunter.
• Accretive Health (AH) was upgraded to outperform from neutral at RW Baird.
• Morgan Stanley upgraded Reinsurance Group (RGA) to overweight from equal weight.
• BofA/Merrill upgraded Clearwire (CLWR) to neutral from underperform.

I first discussed Cigna Corp. (CI) here on May 28, 2009, at a price of $21.89, and shares of insurer have meandered this summer, but just look on that sideways action as a chance to scoop-up shares of a premiere insurer at a decent price.

Cigna's health care unit should lead the way this year, with revenue increasing 15% to 20% in 2010, on both increased subscribers and higher premiums. Further, Cigna's group disability and life insurance units should also notch improved performances in 2010.

Here are some highlights from this past week's earnings coverage on BloggingStocks:

• Blockbuster Inc. (BBI) Q1 net loss was in line with estimates and same-store sales declined, shares also fell.
• CA Inc. (CA) shares sold off on high volume following the Q4 earnings miss and disappointing guidance.
• Cigna Corp. (CI) reported better-than-expected Q1 earnings and higher revenue, and reaffirmed its full-year outlook.
• Cisco Systems Inc. (CSCO) beat Q3 earnings and revenue expectations in the "strongest quarter in our history."
• Dean Foods Co. (DF) lower Q1earnings beat analysts' estimates, but shares fell on heavy volume afterward.
• Denny's Corp. (DENN) bested consensus estimates and year-ago EPS by a penny, but said same-store sales fell.

Humana Inc. (HUM), whose colleagues include Aetna Inc. (AET) and CIGNA Corporation (CI), reported Q1 earnings earlier today. The health insurer isn't doing so well, unfortunately. In late trading, shares were down almost 3% to $43.73. Volume is above the norm, as you might expect.

I've covered many stocks that are near their 52-week highs, but this one doesn't fall into such a desirable category. Alas, the 52-week high on the shares stands at $52.66. And, as you can see from the following one-year chart, the stock began its pullback after it topped out in January. Since then, things haven't been too exciting.

Analyst Upgrades

• Auriga upgraded Intel (INTC) to buy from hold to reflect the stock's relative valuation after channel checks indicated PC shipment plans continue to be solid. The firm raised its target price on shares to $24 from $20.
• Deutsche Bank upgraded RenaissanceRE (RNR) to buy from hold on valuation and believes stock buybacks and reserve releases will drive the company's growth. The firm raised its target price on shares to $65 from $59.
• UBS upgraded Philip Morris (PM) to buy from neutral based on increased confidence in its earnings outlook and relative valuation. The firm raised its target to $54 from $49.
• Chevron (CVX) was raised to outperform from market perform at Bernstein.
• Barnes & Noble (BKS) was upgraded to sell from conviction sell at Goldman Sachs.
• Deutsche Bank (DB) was upgraded to outperform from neutral at Credit Suisse.

Humana Inc. (HUM), who's shares (like other insurers') received a nice bump from the outcome of the special election in Massachusetts, is scheduled to discuss its fourth-quarter 2009 financial results and 2010 guidance in a conference call Monday, Feb. 1, at 9:00 AM (ET). A live webcast of the call will be available at the company's website.

During the three months that ended in December, Humana expanded its Medicare offerings and launched a share buyback program and a social media tool. Analysts surveyed by Thomson Reuters are looking for earnings for that period to have grown 27.7% year over year to $1.48 cents per share. Revenue for the quarter is expected to be 4.0% higher to $7.8 billion.

Analyst Upgrades

• Jefferies upgraded Citrix Systems (CTXS) to buy from hold and raised its target to $48 from $43, citing VMware's (VMW) strong Q4 report and survey results that indicate continued strength for Citrix.
• Citigroup upgraded Amylin Pharmaceuticals (AMLN) to buy from hold on confidence the company's LAR drug will be approved following the approval of Novo Nordisk's (NVO) Victoza. Citi raised its target price for Amylin shares to $27 from $4.
• Baird upgraded Texas Instruments (TXN) to outperform from neutral and raised its target to $30 from $28. The firm believes it is too early to take profits in Texas Instruments and notes that checks continue to indicate a continued recovery in end-demand.
• Lexmark (LXK) was upgraded to overweight from equal weight at Barclays.
• Salix (SLXP) was upgraded to outperform from perform at Oppenheimer.
• Plexus (PLXS) was lifted to outperform from neutral at Credit Suisse.

Today started out strong and stayed positive all day, even if some commented that the highs were not held. The weak dollar helped commodities and helped stocks. A 10.1% October sales rise by the National Association of Realtors by those trying to get the home buyer tax credit didn't hurt either. Ditto for a reiteration that the recession is over.

Here were today's unofficial closing bell levels:

Dow 10,450.04 +131.88 (1.28%)
S&P 500 1,106.13 +14.75 (1.35%)
Nasdaq 2,175.96 +29.92 (1.39%)

Top Day Trader Alerts
Top 10 Analyst Calls
Top Stock/Market Rumors

TheStreet.com's Jim Cramer says the Senate is filled with more-savvy politicians, and the upside for beaten-down names is huge.

Nancy Pelosi has now said her piece. The most unpopular Speaker of the House in the history of Wall Street has gotten her precious health care legislation through the House after ramming through a stimulus package that had far too little infrastructure and far too much pay raise for municipal and state workers, the most powerful interest group in the country.

But this time the Senate sees through it, and the politicians -- despite Pelosi's insistence that Tuesday's election went her way -- know better. There are pages after pages after pages in this bill that look threatening. But here's the rub: This bill's public option, the one that is supposed to be a killer to everything health care, should affect no more than 6 million people over a 10-year period, according to the Congressional Budget Office. In order to get 60 votes in the Senate, even that may prove to be too powerful an option.

President Obama started an intense debate in recent months about national health care. People are concerned about how to pay for the high cost of health care in America and feel it is just too expensive. There has to be a better way!

I like oranges and I grew up in Wisconsin, but in January oranges do not grow very well in Wisconsin. I don't know why -- I am not a horticulturalist -- but maybe it's the lack of sunlight, hard frozen tundra, blowing snow or temperatures of 25 below zero. We could spend a long time pointlessly debating the actual reason.

Analyst upgrades:

• Keefe Bruyette upgraded Popular (NASDAQ: BPOP) to Outperform from Market Perform as it believes the issuance of new common stock in exchange for outstanding preferred and trust preferred stock is a net positive. The firm has a $3.50 target on the stock.
• Merriman upgraded Super Micro Computer (NASDAQ: SMCI) to Buy from Neutral as if finds the currrent valuation compelling and believes the company should directly benefit from improving IT budgets. The firm thinks fair value is in the $9.11-$11.13 range.
• Kaufman Bros. upgraded Netflix (NASDAQ: NFLX) to Buy from Hold after its proprietary survey indicated the company is well positioned longer term. The firm finds the valuation on shares attractive at current levels and raised its target price to $53 from $48.
• Taleo (NASDAQ: TLEO) was upgraded to Buy from Neutral at Janney Montgomery.
• Boardwalk Pipeline (BWP) was upgraded to Neutral from Underperform at BofA/Merrill.
• Lloyds Banking (NYSE: LYG) was upgraded to Buy from Hold at RBS.

Readers of this space know that the bias favors conservative-to-moderate risk companies with demonstrated business models. Moreover, the methodology emphasizes fundamentals, preferably supported by technical indicators.

But every once in a while, the technicals take precedence, particularly in an oversold stock in an out-of-favor sector where the 50-day moving average comes in to play. Cigna (NYSE: CI) is one such case study.